Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
IPO Year: 2022
Exchange: NYSE
Website: https://www.bausch.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $18.00 | Outperform → In-line | Evercore ISI |
| 12/11/2025 | $20.00 | Neutral → Buy | Citigroup |
| 12/2/2025 | $21.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/1/2025 | $16.00 | Neutral | Goldman |
| 5/2/2025 | $20.00 → $15.00 | Buy | H.C. Wainwright |
| 3/28/2025 | $24.00 → $15.00 | Overweight → Equal Weight | Wells Fargo |
| 12/11/2024 | $24.00 → $22.00 | Buy → Neutral | Citigroup |
| 12/2/2024 | $19.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/15/2024 | $19.00 → $25.00 | In-line → Outperform | Evercore ISI |
| 7/10/2024 | $19.00 | Outperform | Raymond James |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
SD - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
10-Q - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
DEF 14A - Bausch & Lomb Corp (0001860742) (Filer)
10-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K/A - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00
Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00
Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00
Goldman initiated coverage of Bausch + Lomb with a rating of Neutral and set a new price target of $16.00
H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously
Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously
Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously
Morgan Stanley downgraded Bausch + Lomb from Overweight to Equal-Weight and set a new price target of $19.00
Evercore ISI upgraded Bausch + Lomb from In-line to Outperform and set a new price target of $25.00 from $19.00 previously
Raymond James initiated coverage of Bausch + Lomb with a rating of Outperform and set a new price target of $19.00
Fastest customizable press release news feed in the world
Blink Triple Care Preservative Free eye drops are made with the same clinically proven formula as Blink Triple Care and provide up to 10 hours of dry eye symptom relief‡ Delivers clinically proven 3-in-1 extended relief,† providing instant, long-lasting dry eye symptom relief and locking in moisture Further strengthens Bausch + Lomb's position in the dry eye category Will be available at most retailers by the end of June 2026 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Triple Care Preservative Free eye drops, which provide instant, long-lasting reli
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be available on the Investor Relations section of the Bausch + Lomb website. About Bausch + Lomb Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changi
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the "Annual Meeting") held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Bernier 331,522,655 4,295,036 11,452,072 Steven H. Collis 331,575,559 4,242,132 11,452,072 Sarah B. Kavanagh 331,548,740
PreserVision AREDS3™ eye vitamins combine clinically proven AREDS2 nutrients recommended by the National Eye Institute (NEI) to help reduce the risk of moderate-to-advanced age-related macular degeneration (AMD) progression with a unique B-vitamin complex* The most advanced PreserVision formula intended to support a broader range of people including those in earlier stages* Triple‑action formula supports macular health: protects, nourishes and boosts* PreserVision AREDS3 was informed by a growing body of scientific evidence on B vitamins in AMD,*2 with a long‑term clinical trial now in planning Now available at most retailers nationwide Bausch + Lomb Corporation (NYSE/TS
Increased cutting speed of 25,000 cuts per minute1 is designed to minimize retinal traction,2 increase vitreous flow1 and reduce infusion pressure fluctuations when used with Adaptive Fluidics.3* Bi-Blade+ provides an average flow rate increase of 25%, enabling more efficient vitreous removal compared to Bi-Blade®.1*† The resulting stability, efficiency and control help boost confidence for retina surgeons to deliver exceptional patient outcomes. Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellar
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company's broad portfolio of products including LUMIFY® redness reliever eye drops, Blink™ NutriTears® nutritional supplement, XIIDRA® (lifitegrast ophthalmic solution) 5%, MIEBO® (perfluorohexyloctane ophthalmic solution), INFUSE®/ULTRA® ONE DAY daily disposable contact
Revenue of $1.244 Billion Revenue Grew 9% as Reported and 6% on a Constant Currency1 Basis Compared to the First Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million Adjusted EBITDA (non-GAAP)1 of $189 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $200 Million Raising Full-Year 2026 Revenue and Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. "We're doing exactly what we said we would: driving sustainable growth and mar
Drawing on more than two decades of scientific evidence, a comprehensive review synthesizes more than 20 human studies highlighting the potential role of certain B vitamins in supporting eye health to help protect against age-related macular degeneration (AMD) PreserVision AREDS3™ eye vitamins combine a unique B-vitamin complex with clinically proven AREDS2 nutrients, intended to expand eye-health support to a broad range of people* PreserVision AREDS3 eye vitamins enhanced with B vitamins are now available in the U.S. and are expected to be at most major retailers by June 2026 The strength of this body of evidence has initiated planning for a long-term clinical trial to evaluate
The Broader Perspective framework sets direction for long-term environmental and social impact Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company's sustainability framework designed to guide future action and accountability. Anchored in the belief that seeing the full picture leads to smarter decisions and greater impact, the new framework highlights how Bausch + Lomb is working across its global operations
Bausch + Lomb's ONE by ONE Recycling program helps prevent small, often overlooked eye health materials from entering landfills and waterways Program highlights the ongoing efforts of eye care practices, patients and consumers in collecting and recycling these used materials The initiative supports the company's long-standing environmental commitments and contributes to its FEWW sustainability metrics – fuel, energy, water and waste Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling
Live Leadership Updates
Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For Against Broker Non-Votes Nathalie Bernier 337,617,248 1,924,336 8,383,437 Gary Hu 337,591,706 1,949,878 8,383,437 Brett Icahn 337,474,287 2,067,297 8,383,437 Sarah B. Kavanagh 337,602,211 1,939,373
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April
SparingVision appoints Joseph C. Papa as Chairman Former Bausch and Lomb Chairman and CEO joins as non-executive independent Chairman as SparingVision enters the clinic with first gene agnostic lead program SPVN06 Paris, April 5, 2023 – SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Joseph C. Papa as its independent Chairman. Papa brings over 30 years of experience in the healthcare sector, having most recently served as Chief Executive Officer and Chairman at Bausch and Lomb Corporation ("Bausch and Lomb") (NYSE:BLCO) a global eye health company. During his tenure, Papa successfully led
Mr. Saunders Brings More Than 25 Years of Health Care Leadership to Bausch + Lomb Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer ("CEO") and chair of the Board of Directors ("Board") of the Company, effective March 6, 2023. Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director. Additionally, effective upon Mr. Saunders' appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board. To
Live finance-specific insights
Revenue of $1.244 Billion Revenue Grew 9% as Reported and 6% on a Constant Currency1 Basis Compared to the First Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million Adjusted EBITDA (non-GAAP)1 of $189 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $200 Million Raising Full-Year 2026 Revenue and Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. "We're doing exactly what we said we would: driving sustainable growth and mar
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 29, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53393 Participant Event Dial-in: +1 (888) 506-
Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026 Time: 8:00 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392 Pa
Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its product pipeline which features potential game-changing innovations in each business unit. T
Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect Solid Business Performance and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our con
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its innovative product pipeline. Additional details will follow closer to the event. Second-Qua
Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 30, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/51713 Participant Event Dial-in: +
This live feed shows all institutional transactions in real time.
SC 13G - Bausch & Lomb Corp (0001860742) (Subject)